Proactive Investors - Run By Investors For Investors
Why invest in FARN?
Faron Pharmaceuticals Oy: THE INVESTMENT CASE

Faron Pharma to provide drug compassionate use of drug; data monitors green light study as it moves into its final few months

The study, codenamed INTEREST, should be wrapped up in the fourth-quarter
Clinical Trial
Faron plans to treat 300 ARDS patients with Traumakine

Faron Pharmaceuticals Ltd (LON:FARN) said it is planning to provide its lead drug on a compassionate use basis once its phase III clinical trial has concluded.

The study, codenamed INTEREST, should be wrapped up in the fourth-quarter.

It was set up to assess the efficacy of Traumakine in treating acute respiratory distress syndrome (ARDS).

Faron said in its latest release that the independent data monitoring committee (IMDC) overseeing the clinical investigation has said the trial should continue unchanged.

Unment medical need

This is consistent with its four previous recommendations.

Faron plans to treat 300 ARDS patients with Traumakine, which performed well in an earlier phase II clinical study.

ARDS is severe lung condition that often results from pneumonia and has mortality rate of 30-45% with 300,000 cases annually in Europe and the US.

"We are very pleased to receive the IDMC's recommendation that the INTEREST study should continue as planned,” said Faron chief executive, Dr Markku Jalkanen.

“The trial is now moving into its final stages and we look forward to closing recruitment during the fourth quarter of 2017.”

'Cleva'  approach

Faron’s pipeline also includes a Clevegen, a pre-clinical drug designed uses the body’s own immune system to tackle cancer.

As the name suggests it does something new and clever that marks out from all the other immuno-oncology treatments coming out of the lab and into early trials.

Consisting of anti-Clever-1 antibody it converts the immune environment around a tumour from being suppressive to immune stimulating.

WATCH: Markku Jalkanen 'excited' to be advancing Clevegen

View full FARN profile View Profile

Faron Pharmaceuticals Oy Timeline

Related Articles

scientist in a lab
September 27 2017
“I strongly believe that ValiRx and its assets offer investors or joint venture partners an increasingly attractive and investable proposition as we strengthen our position among frontrunners in the fields of personalised and precision medicine"
Proteomics International Laboratories: Access latest PPT from Proactive's CEO Sessions
April 13 2017
Richard Lipscombe talked revenue generation and growth path with investors.
mri scanner
July 24 2017
The Assessa PML platform is designed to facilitate the remote transfer, management and storage of MRI scans to help doctors detect progressive multifocal leukoencephalopathy

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use